Table 2.

Baseline characteristics of AIS patients with IDDVT and Non-IDDVT in training cohort

Variables	Training cohort (n = 431)
	Non-IDDVT (n = 335)	IDDVT (n = 96)	P-value
Demographic characteristics
Age (years)	67.6 ± 12.6	73.4 ± 8.4	< 0.001
Gender			0.001
male, n (%)	212 (63.3%)	43 (44.8%)
female, n (%)	123 (36.7%)	53 (55.2%)
Subtype of stroke, n (%)			0.248
Large-artery atherosclerosis	271 (80.9%)	69 (71.9%)
Cardioembolism	36 (10.7%)	18 (18.8%)
Small-artery occlusion	2 (0.6%)	0
Other or undetermined	15 (4.5%)	5 (5.2%)
Unknown	11 (3.3%)	4 (4.2%)
Clinical parameters, n (%)
Lower limb paralysis	112 (33.4%)	57 (59.4%)	< 0.001
Current pneumonia	49 (14.6%)	35 (36.5%)	< 0.001
Atrial fibrillation	48 (14.3%)	33 (34.4%)	< 0.001
Arterial hypertension	256 (76.4%)	71 (74.0%)	0.620
Diabetes mellitus	115 (34.3%)	36 (37.5%)	0.566
Current malignant tumor	11 (3.3%)	10 (10.4%)	0.004
Current uarthritis	15 (4.5%)	2 (2.1%)	0.288
Laboratory parameters
Albumin (g/L)	37.1 ± 4.2	36.4 ± 4.0	0.170
Fast blood glucose (mmol/L)	5.9 ± 2.2	6.0 ± 2.4	0.556
SCr (μmol/L)	68.0 (57.0–83.0)	63.5 (52.0–78.2)	0.016
Hcy (μmol/L)	6.1 ± 3.8	6.3 ± 3.9	0.697
INR	1.1 ± 0.3	1.1 ± 0.2	0.673
Fibrinogen (g/L)	3.6 ± 1.5	3.6 ± 1.6	0.848
D-Dimer (mg/L)	1.2 (0.8–2.1)	1.8 (1.2–3.7)	< 0.001
CRP (mg/L)	7.3 (3.2–18.6)	14.6 (5.9–31.5)	0.008
hs-CRP (mg/L)	3.5 (1.0–11.8)	8.5 (3.9–32.4)	0.021
1 n (%)
Anticoagulants	101 (30.1%)	37 (38.5%)	0.120
Antiplatelet	281 (83.9%)	77 (80.2%)	0.398
Lipid-lowering agents	324 (96.7%)	93 (96.9%)	0.938
Thrombolysis treatment	12 (3.6%)	8 (8.3%)	0.051

NOTE. CRP c-reactive protein; Hcy homocysteine; hs-CRP high-sensitivity C-reactive protein; IDDVT isolated distal deep venous thrombosis; SCr serum creatinine concentration